evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 100%Moderate 0 · 0%High 0 · 0%

Lower vs higher cumulative dose dexamethasone regimen

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).

1 finding from 1 review

Later vs earlier initiation of dexamethasone therapy

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).

1 finding from 1 review

Pulse vs continuous dexamethasone therapy

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).

1 finding from 1 review

Individual tailored vs continuous tapered dexamethasone regimen

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Individual tailored showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with continuous tapered dexamethasone regimen (low certainty).

1 finding from 1 review